Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

By I. Anderson. Journal of Affective Disorders, 2000

746 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. (2002, methodology): “Tricyclic antidepressants and selective serotonin (SSRIs) and norepinephrine reuptake inhibitors are similar in their efficacy.(2,3) The SSRIs are marginally better tolerated, but the differences are small.”
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders (2015, background): “Lithium, a widely supported and used augmentation agent, is found to be more effective than placebo in augmentation of TCAs, SSRIs and other antidepressants (Bauer et al., 2000; Crossley and Bauer, 2007).”
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines (2015, background): “Presentations on key areas with an emphasis on systematic reviews and randomised controlled trials (RCTs) were made by each co-author of the guidelines, followed by discussion within the whole group about the quality of evidence and its implications.”